The meeting of Cannabinoids and the Endocannabinoid System
History was made at the meeting of Cannabinoids with the human Endocannabinoid system (ECS), an interaction that derived benefits far beyond modern medicine. Cannabis leaf extract has been an integral component of ayurvedic medicine, and the ECS is a system responsible for regulating and enhancing- physical and cognitive processes.
Globally, cannabis-based medication has received much recognition, and now India is set to harness the benefits of a plant that has been an integral part of its ayurvedic history. As cannabis makes a comeback into our lives, we reimagined this wonder crop, into little drops that care with;
CannaReleaf™ Pain Management (Vijayasat Swarna), which includes an ayurvedic formula that is designed to aid people battling chronic and neuropathic ailments. A product that helps mitigate the symptoms of chronic and neuropathic pain, inflammation, nausea, mood, appetite, and senile insomnia. The full-spectrum of cannabinoids in cannabis leaf-based medication provides you with a natural treatment for symptomatic relief. The following information describes how Cannabis is said to help with chronic symptoms-
Manages chronic and neuropathic pain
Pain and inflammation are the body’s physiological responses to tissue injury, infection, and genetic changes. These responses can be divided into two phases- acute and chronic.
Acute pain is characterised by certain changes in the body like local vasodilation, increased capillary permeability, accumulation of fluid and blood proteins in the interstitial spaces, and release of certain pro-inflammatory markers like cytokines and lymphokines.
Pain is produced by these pro-inflammatory agents that also lead to hyperalgesia through the activation of corresponding receptors, which are expressed by nociceptive (pain) terminals. If the progression of the disease is not stopped or resolved by interventional therapy, the inflammatory process progresses towards chronic/subacute inflammation, which is characterised by immunopathological changes like overexpression of proinflammatory genes.
Dysregulation of cellular signalling and the loss of barrier function. A chronic state of inflammation plays an important role in the onset of classic inflammatory diseases (e.g. arthritis) but also of various diseases, including cardiovascular and neurodegenerative diseases, diabetes, cancer, and asthma.
The suppression or inhibition of inflammatory/pro-inflammatory mediators using synthetic anti-inflammatory compounds (both steroidal and non-steroidal) is one of the major routes for the treatment of inflammatory disorders. However, several common side effects, including gastric irritation and ulceration, renal and hepatic failure, haemolytic anaemia, asthma exacerbation, skin rashes, are often associated with the use of synthetic anti-inflammatory drugs
There is an increasing amount of evidence that the endocannabinoid system actively participates in the pathophysiology of osteoarthritis-related joint pain.
Preclinical and clinical data support the potentially effective anti-inflammatory properties of endocannabinoid agonists that target CB2 receptors. CBD is one such agonist that targets and binds to the CB 2 receptor to alleviate pain and inflammation.
Reduces inflammation & nausea
Considerable evidence demonstrates that manipulation of the endocannabinoid system regulates nausea and vomiting in humans. When a molecule (CB1 agonist like THC) binds to the CB1 receptor, it suppresses vomiting, which is reversed by CB1 antagonists, and CB1 inverse agonism promotes vomiting. Manipulation of the Endocannabinoid system has shown evidence of regulation of nausea and vomiting in humans. In a classic example of ligand-receptor binding system cannabinoids like THC and CBD bind to the CB1 receptor to alleviate the feelings of nausea and vomiting. This has been portrayed in humans.
The human body responds to external and internal stimuli in many ways. Ordinarily, when the stomach is empty it releases a hormone called ghrelin, a message to the brain that it's time for food. Cannabinoids have shown evidence that they trigger a ghrelin surge. Cannabinoids, particularly delta-9 tetrahydrocannabinol (THC), are responsible for its psychological effects. The ability of THC to stimulate appetite is valuable since many illnesses cause extreme appetite loss which reduces the quality of life and slows recovery.
Numerous physiological functions such as mood, cognition, feeding behaviour and pain perception, are modulated by the ECS. CB1Rs represent the most numerous GPCRs in the adult brain, particularly expressed in regions involved in reward, addiction and cognitive functions, including the amygdala, cingulate cortex, prefrontal cortex, ventral pallidum, caudate, nucleus accumbens, ventral tegmental area, and lateral hypothalamus.
When an agonist of the CB1 Receptor, like THC, binds to the receptor in that part of the brain responsible for mood/emotional homeostasis, it exerts a mood-elevating effect. This kind of effect is exerted by endocannabinoids, but in the absence or inadequate production of endocannabinoids, Phyto-supplementation of cannabinoids can be an alternative.
Aids Senile Insomnia
The cannabis plant has been used for centuries as a sleep aid. Contemporary scientific research has measured the relaxing and sedative effects of cannabis that people have known and experienced since ancient times. In particular, cannabis makes falling asleep easier. One recent study found that cannabis shortens the time it takes to fall asleep, both for people with sleep problems, and people who fall asleep without trouble. Among people with active difficulty falling asleep, cannabis use resulted in an average of 30 minutes less time in falling asleep. The study also included a group of people who were able to fall asleep without difficulty. Among this group of strong sleepers, cannabis helped them fall asleep even faster, by fifteen minutes.
Please feel free to reach out to us for more information and professional medical guidance.
Written by- Siddhant Mistry